Normal view
-
Journal of Medical Internet Research
-
Using Large Language Models to Assess the Consistency of Randomized Controlled Trials on AI Interventions With CONSORT-AI: Cross-Sectional Survey
Background: Chatbots based on large language models (LLMs) have shown promise in evaluating the consistency of research. Previously, researchers used LLM to assess if randomized controlled trial (RCT) abstracts adhered to the CONSORT-Abstract guidelines. However, the consistency of artificial intelligence (AI) interventional RCTs align with the CONSORT-AI standards by LLMs remains unclear. Objective: The aim of this study is to identify the consistency of randomized controlled trials on AI inter
-
Nature - Issue - nature.com science feeds
-
A fully open AI foundation model applied to chest radiography
Nature, Published online: 11 June 2025; doi:10.1038/s41586-025-09079-8Ark+, a fully open artificial intelligence foundation model, demonstrates exceptional capabilities in diagnosing common, rare and novel thoracic diseases.
A fully open AI foundation model applied to chest radiography
Nature, Published online: 11 June 2025; doi:10.1038/s41586-025-09079-8
Ark+, a fully open artificial intelligence foundation model, demonstrates exceptional capabilities in diagnosing common, rare and novel thoracic diseases.-
Omics In Lung
-
RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis
Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.ABSTRACTA user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognost
RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis
Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.
ABSTRACT
A user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognostic model using coxBoost + RSF algorithms in lung cancer highlighted m6A as a suitable marker to guide therapeutic strategy. RMethyMD provides a comprehensive resource and multiomics analysis to explore m6A-based prognostic and clinical values, thereby contributing to aiding personalized cancer therapy.
PMID:39809358 | DOI:10.1016/j.canlet.2025.217462
-
Nature - Issue - nature.com science feeds
-
Author Correction: π-HuB: the proteomic navigator of the human body
Nature, Published online: 23 December 2024; doi:10.1038/s41586-024-08555-xAuthor Correction: π-HuB: the proteomic navigator of the human body
Author Correction: π-HuB: the proteomic navigator of the human body
Nature, Published online: 23 December 2024; doi:10.1038/s41586-024-08555-x
Author Correction: π-HuB: the proteomic navigator of the human body-
Cell Death Discovery nature.com science feeds
-
KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma
Cell Death Discovery, Published online: 24 May 2024; doi:10.1038/s41420-024-02020-4KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma
KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma
Cell Death Discovery, Published online: 24 May 2024; doi:10.1038/s41420-024-02020-4
KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma-
Nature - Issue - nature.com science feeds
-
Genome-wide characterization of circulating metabolic biomarkers
Nature, Published online: 06 March 2024; doi:10.1038/s41586-024-07148-yA meta-analysis of genome-wide association studies for 233 circulating metabolites from 33 cohorts reveals more than 400 loci and suggests probable causal genes, providing insights into metabolic pathways and disease aetiology.
Genome-wide characterization of circulating metabolic biomarkers
Nature, Published online: 06 March 2024; doi:10.1038/s41586-024-07148-y
A meta-analysis of genome-wide association studies for 233 circulating metabolites from 33 cohorts reveals more than 400 loci and suggests probable causal genes, providing insights into metabolic pathways and disease aetiology.-
Nature - Issue - nature.com science feeds
-
Scientific discovery in the age of artificial intelligence
Nature, Published online: 02 August 2023; doi:10.1038/s41586-023-06221-2The advances in artificial intelligence over the past decade are examined, with a discussion on how artificial intelligence systems can aid the scientific process and the central issues that remain despite advances.
Scientific discovery in the age of artificial intelligence
Nature, Published online: 02 August 2023; doi:10.1038/s41586-023-06221-2
The advances in artificial intelligence over the past decade are examined, with a discussion on how artificial intelligence systems can aid the scientific process and the central issues that remain despite advances.-
Cell Death Discovery nature.com science feeds
-
The trigger for pancreatic disease: NLRP3 inflammasome
Cell Death Discovery, Published online: 14 July 2023; doi:10.1038/s41420-023-01550-7The trigger for pancreatic disease: NLRP3 inflammasome
The trigger for pancreatic disease: NLRP3 inflammasome
Cell Death Discovery, Published online: 14 July 2023; doi:10.1038/s41420-023-01550-7
The trigger for pancreatic disease: NLRP3 inflammasome-
Oncogenesis - nature.com science feeds
-
ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1
Oncogenesis, Published online: 04 August 2022; doi:10.1038/s41389-022-00418-2ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1
ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1
Oncogenesis, Published online: 04 August 2022; doi:10.1038/s41389-022-00418-2
ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1